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ABSTRACT  
Background PMS2-associated Lynch syndrome is characterized by a relatively low colorectal cancer (CRC) 
penetrance compared to other Lynch syndromes. However, age at CRC diagnosis varies widely and a strong 
genetic anticipation effect has been suggested for PMS2 families. In this study we examined proposed genetic 
anticipation in a sample of 152 European PMS2 families. 
Material and methods The 152 families (637 family members) that were eligible for analysis were mainly 
clinically ascertained via clinical genetics centers. We used weighted Cox-type random effects model, adjusted 
by birth-cohort and sex, to estimate the generational effect on the age of onset of CRC. Probands and young 
birth-cohorts were excluded from the analyses. Weights represented mutation probabilities based on kinship 
coefficients, thus avoiding testing bias.  
Results Family data across three generations, including 123 CRCs, were analyzed. When compared to the first 
generation, the crude Hazard Ratio (HR) for anticipation was 2.242 (95%CI: 1.162-4.328) for the second and 
2.644 (95%CI: 1.082-6.464) for the third generation. However, after correction for birth-cohort and sex the 
effect vanished (HR=1.302 (95%CI: 0.648-2.619) and HR=1.074 (95%CI: 0.406-2.842) for second and third 
generations, respectively).  
Conclusions Our study did not confirm previous reports of genetic anticipation in PMS2-associated Lynch 
syndrome. Birth-cohort effect seems the most likely explanation for observed younger CRC diagnosis in 
subsequent generations, particularly since there is currently no commonly accepted biological mechanism that 
could explain genetic anticipation in Lynch syndrome. 
Impact This new model for studying genetic anticipation provides a standard for rigorous analysis of families 
with dominantly inherited cancer predisposition.  
 
KEY WORDS: modifier, penetrance, colon cancer, HNPCC, phenotype 
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INTRODUCTION 
Lynch syndrome is the most common cause of hereditary colorectal cancer, accounting for 3-5% of all 
colorectal cancers diagnosed annually.1 The underlying cause is a heterozygous pathogenic germline variant in 
one of the mismatch repair genes: MLH1, MSH2 (EPCAM), MSH6 or PMS2. The latter gene is associated with a 
lower estimated penetrance and thus a markedly lower incidence of cancer. However, PMS2 families show 
phenotypic variability, with very wide differences in age at colorectal cancer diagnosis. While the mean age of 
onset for colorectal cancer for PMS2-associated Lynch syndrome is around 60, some PMS2 carriers develop 
colorectal cancer as early as 23.2-4 Several external and internal modifiers have been suggested as possible 
explanations, one of which, genetic anticipation, has been the subject of much debate.5-9 The phenomenon of 
genetic anticipation is clearly defined in genetic disorders involving trinucleotide repeats such as Huntington’s 
disease, where expansion of the repeat in subsequent generations is a clear precursor of disease.10 However, a 
mechanism of this type has not been described in Lynch syndrome, which in fact requires a second somatic hit 
for mismatch repair (MMR) deficiency to occur. A single germline mutation in one of the MMR genes does not 
confer haploinsufficiency.11 
Nevertheless, genetic anticipation in Lynch syndrome and other dominantly inherited cancer predisposition 
syndromes has been reported by several groups. If a genetic anticipation effect could indeed be confirmed it 
would be of clinical utility in the development of individually-tailored surveillance schemes. The only report of 
genetic anticipation in PMS2-associated Lynch syndrome families found a very strong effect (anticipation of 7.3 
years per subsequent generation).12 However, sample size in that study was small, including only 12 PMS2 
families. In the same study, carriers of pathogenic germline variants in other MMR genes showed only small or 
absent anticipation effects.12 By investigating a much larger cohort of 152 families, our aim was to reassess the 
possibility of genetic anticipation in PMS2-associated Lynch syndrome. 
 
MATERIALS AND METHODS 
Description of the cohort 
Pedigree data on European families carrying a segregating pathogenic PMS2 variant were originally collected 
from clinical genetic departments between 2009 and 2012, as previously described.4 Further families were 
collected between 2012 and 2017 and an extensive description is available elsewhere (ten Broeke et al, 2018, 
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in-press at Journal of Clinical Oncology). The PMS2 families included originated from the Netherlands, Norway, 
Germany, Sweden, Denmark and Spain. Data collection was approved by the local ethical review board (Leiden 
University Medical Center Ethics Review Board, protocol ID: P01.019). This dataset consisted of clinically 
ascertained families where variant analysis was initiated due to (histological) pre-screening by 
immunohistochemistry and/or microsatellite instability, usually because a family met Bethesda criteria.13 Data 
collection from patient records included demographic data, family pedigrees, age and location of cancer 
diagnosis, polypectomy, and hysterectomy if applicable. When available, clinical and pathological diagnoses 
were confirmed using patient records.  
 
Statistical analysis 
The outcome of interest was age at first diagnosis of colorectal cancer. The follow-up time was defined as the 
time elapsed from birth till the first colorectal cancer diagnosis or censoring. Censoring occurred on the basis 
of last known other cancer diagnosis, death or administrative censoring at age of last contact with the family, 
whichever occurred last. Family members with bi-allelic PMS2 mutations were excluded from the analysis 
given the severe and markedly different phenotype of these constitutional mismatch repair deficiency 
(CMMRD) patients.  Genetic anticipation was estimated as the effect of generation on a person’s hazard for 
cancer diagnosis, using a shared gamma frailty proportional hazard model:  𝜆 𝑡 = 𝑢 𝜆 𝑡 exp (𝛃𝒁 + 𝛄𝑿 ), 
where 𝑡  is the age at first diagnosis of colorectal cancer or the age at censoring for member j in family i, 𝜆 𝑡  refers to the baseline hazard, which is left completely unspecified (Cox-type model), 𝛃 = (β , β ) 
contains the main effects of interest, the regression coefficient of second and third generation 𝒁 = (𝑍 , 𝑍 ), 
taking the first oldest generation of each family as reference and u > 0 refers to an unobserved random effect 
(frailty) shared by the members of the same family. This unobserved heterogeneity shared within families was 
assumed to follow a gamma distribution (normal frailty was also checked as a sensitivity analysis). 𝛄 contains 
the effect of person-specific covariates 𝑿 included in a second adjusted analysis, namely sex and year of birth.  
Since not all family members were tested for PMS2 variants, mutation probabilities based on kinship 
coefficients were used as analytical weights to avoid possible testing bias and increase efficiency. Specifically, 
the weight for individual j,  𝑤 = 𝑃(𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛|𝑓𝑎𝑚𝑖𝑙𝑦 ℎ𝑖𝑠𝑡𝑜𝑟𝑦 𝑜𝑓 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛) is given by the kinship 
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coefficient between individual  j and the closest family member with observed mutation.  Mutation 
probabilities are included as case weights in the corresponding penalized score function provided in the R 
package survival.14 Remaining ascertainment bias was controlled by excluding the probands and focusing on 
individuals born before 1950, so that all included individuals were at risk for at least 65 years, hence avoiding 
potential bias due to right truncation. Statistical significance was established at 5%. 
 
RESULTS 
A description of the cohort is given in tables 1 and 2. The analysis included 637 family members with 123 
colorectal cancers (table 1), divided over 3 generations (table 2). After weighting, the estimated number of 
mutation carriers in the sample is 360. Results of the Cox-type random effects model are given in table 3, 
which shows increased hazard ratios (HRs) in the crude analysis (HR=2.24, 95% CI=1.16-4.33 for the second 
generation and HR=2.64, 95% CI=1.08-6.46 for the third generation, respectively). After correction for gender 
and birth-cohort, HR size decreased (half of the crude effect) and was no longer statistically significant (as the 
corresponding confidence intervals included 1). The adjusted analysis showed a strong effect of year of birth 
(HR=1.05, 95% CI = 1.02-1.07), equaling a roughly 5% increase of risk for every year towards the present time. 
These results suggest that the estimated anticipation effect in the crude analysis is strongly confounded by 
birth-cohort and that the apparent effect of generation is mainly explained by secular trends in colorectal 
cancer diagnosis. The use of normal random effects instead of gamma provided very similar results in terms of 
genetic anticipation, sex and birth-cohort effects (results available in supplementary table 1). 
 
DISCUSSION 
The occurrence of genetic anticipation in Lynch syndrome has been a subject of considerable debate and gene-
specific effects have been offered as an explanation. After correction for birth-cohort, our analysis found no 
evidence of anticipation in a very large cohort of PMS2-associated Lynch syndrome families. A rise in colorectal 
cancer incidence as well as lower age at diagnosis in recent decades in the general population has been 
previously observed.15-17 Reasons for this might include better detection with more sensitive screening 
methods, lifestyle factors, population-based screening protocols and increased life-expectancy. These factors 
could also play a role in Lynch syndrome patients. Other factors that could cause a false genetic anticipation 
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signal that are specific to Lynch syndrome, and other dominantly inherited cancer predisposition syndromes in 
general, involve the genetic diagnostic process. For example, after identification of the proband, pre-
symptomatic family members are tested and subsequently screened if they carry the PMS2 variant. This might 
lower age at diagnoses of indolent tumors which might not have presented itself otherwise. An alternative 
explanation for false genetic anticipation effect may be that colorectal cancer diagnosis in older generations 
may have been underreported. 
Analysis of dominantly inherited cancer predisposition is potentially influenced by several forms of bias. First, 
clinically ascertained families are accompanied by a selection bias, as they were selected due to their 
compliance with clinical selection criteria and are therefore often severely affected, i.e. many family members 
with (colorectal) cancer or an unusually low age at diagnosis. A problem arises when the phenotype is not 
caused by the pathogenic PMS2 variant alone but is affected by other modifying factors. This is especially 
problematic for PMS2, as selection based on, for example, the Bethesda guidelines is influenced by criteria for 
classic Lynch families involving mainly pathogenic MLH1 or MSH2 variants. In the case of PMS2 variants, it is 
well documented that variants are at most only moderately penetrant2, 4, suggesting that PMS2 families 
selected on the basis of these criteria alone will include many relatively severely affected members. However, 
due to universal screening for mismatch repair deficiency in all colorectal cancers below age 70 in most 
Western countries, a rise in unselected PMS2 carriers is expected.18  
A second form of bias that should be considered is testing bias due to the fact that people affected 
with (colorectal) cancer (at a young age) are more likely to be tested for the presence of a PMS2 variant. 
Probands (i.e. the first person in the family with a confirmed pathogenic germline PMS2 variant) are the most 
notable example of this, and all probands were therefore excluded from our analysis. Moreover, we also used 
analytical weights to model mutation probabilities. For example, first-degree relatives of a confirmed carrier 
that were not tested were given a weight of 0.5, whereas second-degree relatives had a weight of 0.25. This 
approach also helped improve the power of the analysis.  
Although there is no clear biological rationale for genetic anticipation in Lynch syndrome, alternative 
explanations besides birth-cohort have been proposed in other studies. It is generally accepted that families 
with Li-Fraumeni syndrome (which strongly predisposes to several forms of cancer) exhibit anticipation that 
cannot be explained by a birth-cohort effect.19, 20 A recent whole genome sequencing study of germline DNA in 
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13 Li-Fraumeni syndrome cases did not find increased DNA copy-number variations, suggesting that CNVs do 
not mediate the genetic anticipation effect. The authors proposed an alternative model explaining apparent 
anticipation in which variants from the non-carrier parent influence tumorigenesis in the offspring of TP53 
mutation carriers with late onset of cancer.21 In other words, parents with relatively late onset might have 
offspring that are more prone to tumorigenesis due to inheritance of specific risk increasing variants from the 
non-carrier parent. Similar mechanisms may also influence cancer age of onset and thus explain variability 
within families and birth-cohorts in Lynch syndrome. Another suggested biological mechanism involves 
telomeres. Retrospective studies have identified shorter telomeres in colorectal cancer cases vs. controls, 
arguing that shorter telomeres cause chromosomal instability and might therefore lead to cancer. Indeed, 
shortening of telomeres was also observed in peripheral blood in Lynch Syndrome patients affected with 
colorectal cancer, compared to non-affected mutation carriers.22 This finding has not been replicated in 
prospective studies, suggesting that the shortening of telomeres might be the result of the cancer process 
rather than a causative factor.23 
Ours is not the first study to report bias in anticipation analysis due to birth-cohort effects. Similar 
results have been found in other genetic syndromes, including a study by Guindalini et al. in BRCA1/2 
families.24 This study corrected for various types of bias by excluding probands, including mutation 
probabilities and correcting for birth-cohort. Our analysis followed similar principles and incorporated 
additional flexibility in the specification of the regression model. Our model is semi-parametric, since the 
baseline hazard is left completely unspecified and is therefore more flexible than the model used by Guindalini 
et al., which was based on a parametric specification of the underlying time-to-event data distribution.25 
Moreover, we have allowed for a more flexible, non-linear effect of generation, considering two possibly 
different effects for second and third generations with respect to the first, oldest generation. Previous reports 
have relied on a linear and perhaps too stringent specification of the anticipation effect. We also used gamma 
random effects in our main analyses and checked the impact of random effect specification by also considering 
normal random effects. The results regarding anticipation and birth-cohort effect remained the same. Normal 
random effect modeling of hazard was previously used by von Salome et al. in a study in which the authors 
reported strong genetic anticipation in twelve PMS2 families.12 However, cohort effects were not considered 
and a linear specification was assumed for the generation effect. Daugherty et al. also used a Cox-type hazard 
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regression method to study anticipation in lymphoproliferative tumors but adopted a less flexible approach 
since random effects were not considered and hence family-specific effects could not be captured.26 
Nevertheless, these authors also identified a confounding effect of secular trends on apparent anticipation 
effects of generation. 
Regression strategies have previously been shown to be preferable over hypothesis testing based on 
parent-child pairs.9 Since our regression strategy is flexible, it is possible to reasonably reflect the underlying 
structure of the data while still getting interpretable results and preserving sufficient power. Boonstra et al. 
have reported genetic anticipation in Lynch syndrome based on an alternative specification that allowed for 
family-specific anticipation effects (random slopes).27 Such specification is flexible since it allows for a specific 
effect of generation in each family, although the effect is linear within families. We have introduced flexibility 
in a different manner, by allowing for a non-linear fixed anticipation effect, which is less dependent in the 
chosen parametric family on random effects. Moreover, Boonstra et al. did not directly estimate cohort effects 
based on the sample, but inferred them from external cancer incidence registries (not specific for Lynch 
syndrome) on the basis of a piecewise (5-year knots) linear hazard assumption.27 Misspecification in this step 
may have introduced bias in the estimated anticipation effect. Despite our efforts to account for possible bias 
in our analysis strategy, the retrospective nature of our data is still a limitation of our study. Similarly, in an 
effort to avoid ascertainment bias we excluded some data, leading to a reduction in power. Models which can 
accommodate right truncated data should be developed and used in this field. A last limitation is that the 
weights that were used to estimate the probability of carrying the familial PMS2 mutation only took into 
account degree of kinship, but not the presence of a cancer phenotype, e.g. colorectal cancer. Including this 
factor in the weigh calculation is complicated given the complex pedigree structure. Moreover, recent work by 
our own group suggests that the lifetime risk for colorectal cancer is only 2-3 times increased compared to the 
general population (ten Broeke et al, 2018, in-press at Journal of Clinical Oncology), which may cause 
misspecification of PMS2-associated colorectal cancer as this cancer also occurs frequently in the general 
population.  
 
In conclusion, after correction for birth-cohort, our study did not confirm previous findings of genetic 
anticipation in PMS2-associated Lynch syndrome patients. Therefore, anticipation cannot be used in individual 
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risk estimation. Given the large phenotypic variability in Lynch syndrome patients, future studies should focus 
on other potential modifiers. 
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TABLES 
 
Table 1: Cohort description 
Number of families 152
Family members included 637
Mutation status 
100%* 176 
[50%,100%) 282 
[25%,50% ) 158 
[12.5%,25%) 21 
Colorectal cancer 
Number 123
Mean Age (s.d.) 69.58 (12.94)
Median age (IQR) 71 (62-77)
s.d.: Standard deviation; IQR: Interquartile range.
* Confirmed and obligate carriers. 
Note: Probands were excluded from the analysis. 
 
 
Table 2: Number of family members for each generation and median year of birth 
Generation Number Median (IQR)
1  153  1912 (1902-1924)
2 399 1927 (1918-1938)
3 85 1943 (1937-1950)
IQR: Interquartile range 
 
 
Table 3: Results of Cox model 
  
Crude analysis Adjusted analysis*
HR 95% CI HR 95% CI
Generation 1 reference reference 
Generation 2 2.24 1.16 to 4.33 1.30 0.65 to 2.62
Generation 3 2.64 1.08 to 6.46 1.07 0.41 to 2.84
*Adjusted for: gender and year of birth
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